A Multicenter, Open-label, Single-dose Pharmacokinetic and Safety Evaluation of HORIZANT (Gabapentin Enacarbil Extended-release Tablets) in Adolescents Aged 13 to 17 Years Old With Moderate-to-severe Primary Restless Legs Syndrome
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Gabapentin enacarbil (Primary)
- Indications Restless legs syndrome
- Focus Pharmacokinetics
- Sponsors Arbor Pharmaceuticals; XenoPort
- 01 Nov 2017 Planned End Date changed from 1 Jun 2016 to 19 Jul 2017.
- 01 Nov 2017 Planned primary completion date changed from 1 May 2016 to 19 Jul 2017.
- 01 Nov 2017 Status changed from recruiting to discontinued.